JP Morgan Chase
VRCA icon

JP Morgan Chase’s Verrica Pharmaceuticals VRCA Stock Holding History

JP Morgan Chase’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224 Hold
47
– – ﹤0.01% 7243
2025
Q4 		$391 Buy
+47
New +$260 ﹤0.01% 7100
2025
Q2 		– Sell
-2,031
Closed -$8.98K – 7682
2025
Q1 		$8.98K Buy
2,031
+1,079
+113% +$6.98K ﹤0.01% 6327
2024
Q4 		$6.66K Buy
952
+65
+7% +$714 ﹤0.01% 6459
2024
Q3 		$12.9K Buy
887
+22
+3% +$991 ﹤0.01% 6322
2024
Q2 		$63.1K Sell
865
-10
-1% -$768 ﹤0.01% 5757
2024
Q1 		$51.8K Sell
875
-484
-36% -$26.7K ﹤0.01% 5925
2023
Q4 		$99.5K Hold
1,359
– – ﹤0.01% 5734
2023
Q3 		$52.8K Sell
1,359
-428
-24% -$21.8K ﹤0.01% 5785
2023
Q2 		$103K Buy
1,787
+1,663
+1,341% +$101K ﹤0.01% 5441
2023
Q1 		$8K Hold
124
– – ﹤0.01% 6174
2022
Q4 		$3K Sell
124
-146
-54% -$3.9K ﹤0.01% 6267
2022
Q3 		$8K Buy
270
+162
+150% +$5.55K ﹤0.01% 6008
2022
Q2 		$2K Sell
108
-829
-88% -$41.7K ﹤0.01% 6309
2022
Q1 		$76K Sell
937
-1,522
-62% -$125K ﹤0.01% 5626
2021
Q4 		$225K Sell
2,459
-592
-19% -$67K ﹤0.01% 5287
2021
Q3 		$382K Sell
3,051
-1,283
-30% -$144K ﹤0.01% 4878
2021
Q2 		$490K Buy
4,334
+1,560
+56% +$189K ﹤0.01% 4709
2021
Q1 		$421K Buy
2,774
+2,223
+403% +$308K ﹤0.01% 4788
2020
Q4 		$63K Buy
551
+87
+19% +$8K ﹤0.01% 5105
2020
Q3 		$37K Sell
464
-88
-16% -$7.21K ﹤0.01% 5024
2020
Q2 		$60K Buy
552
+137
+33% +$15.8K ﹤0.01% 4775
2020
Q1 		$45K Sell
415
-10
-2% -$1.32K ﹤0.01% 4759
2019
Q4 		$67K Buy
425
+2
+0.5% +$295 ﹤0.01% 5031
2019
Q3 		$62K Buy
423
+69
+19% +$7.69K ﹤0.01% 5080
2019
Q2 		$34K Buy
354
+93
+36% +$8.72K ﹤0.01% 5314
2019
Q1 		$28K Sell
261
-999
-79% -$115K ﹤0.01% 5316
2018
Q4 		$103K Buy
1,260
+1,126
+840% +$137K ﹤0.01% 4842
2018
Q3 		$22K Buy
+134
New +$22.9K ﹤0.01% 5406

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's VRCA Position: Q1 2026 in Review

JP Morgan Chase held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 47 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #7243.

JP Morgan Chase first reported a position in VRCA in Q3 2018 and has held it in 29 quarters since. The position peaked at $490K in Q2 2021. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • JP Morgan Chase held 47 shares of Verrica Pharmaceuticals worth $224 as of Q1 2026.
  • JP Morgan Chase left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7243 holding.
  • JP Morgan Chase first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 29 quarters since.
  • JP Morgan Chase's Verrica Pharmaceuticals position peaked at $490K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.